People who used lipophilic (fat-soluble) statins like atorvastatin and simvastatin had the greatest outcomes and ...

HealthDay News — For patients with chronic liver disease, statin use is associated with a reduced risk for hepatocellular carcinoma (HCC) and hepatic decompensation, according to a study published ...

Hepatocellular carcinoma (HCC) represents about 90% of all cases of liver cancer and has a poor prognosis, with a 5-year survival rate of about 18%. Previous findings had shown that RNA ...

Harvard Medical School researchers have found that statin use significantly reduces the risk of hepatocellular carcinoma (HCC ...

Direct-acting antivirals (DAAs) have dramatically changed the landscape of chronic hepatitis C virus (HCV) treatment and ...

Statin use in patients with chronic liver disease was associated with a reduced risk of hepatocellular carcinoma (HCC) and ...

Hepatitis C virus (HCV) infection remains a major global health burden, affecting millions worldwide and contributing significantly to hepatocellular carcinoma (HCC) development.

Liver cancer, predominantly hepatocellular carcinoma (HCC), remains one of the most aggressive and leading causes of ...

2 The current standard of care for frontline treatment of unresectable HCC is atezolizumab (Tecentriq; Genentech) plus bevacizumab (Avastin; Genentech). 4 Other frontline options are durvalumab ...

Discover how statin use in chronic liver disease lowers liver cancer and decompensation risks, with added benefits from ...

HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, ...